Combining Biologic Agents in Inflammatory Bowel Disease

G&H What is the rationale for combining biologic agents in inflammatory bowel disease? MA Most of the biologic agents that gastroenterologists are currently using are […]

Perianal Fistulas in Patients With Crohn’s Disease, Part 1: Current Medical Management

Abstract: Despite significant advances in the treatment of luminal inflammatory bowel disease, the treatment of perianal fistulas remains a clinical challenge. Perianal fistulas are traditionally […]

Targeting Mucosal Healing in Crohn’s Disease

Abstract: The goal of medical treatment for Crohn’s disease includes improving patients’ quality of life while reducing the need for hospitalization and surgery. The current medical armamentarium includes 5-aminosalicylates, corticosteroids, immunomodulators, and biologic agents. In the past, response to treatment was measured by clinical improvement in symptoms; however, with the advent of disease-modifying medications, mucosal healing has emerged as an increasingly important goal of therapy. Mucosal healing, or endoscopic remission, is associated with increased rates of clinical remission, fewer hospitalizations, and fewer abdominal surgeries. Both the immunomodulator and biologic classes of medications are effective at inducing mucosal healing. Despite several limitations, mucosal healing has become a desirable and valid measure of disease activity.